The CCPG1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting CCPG1 in the HAP1 cell line. This model enables loss-of-function studies of CCPG1, a cell cycle regulator, without the constraints of clonal selection. The polyclonal format captures diverse editing events, offering a representative population for robust functional analyses in cancer research.
HAP1 is a male near-haploid chronic myeloid leukemia cell line derived from KBM-7, featuring adherent growth and a haploid karyotype. Its single allelic copy facilitates efficient CRISPR/Cas9-mediated gene disruption, eliminating confounding diploid effects. Widely adopted for genetic screens and functional genomics, HAP1 provides a clean background for knockout studies, enabling direct association of phenotypes with gene perturbation.
CCPG1 encodes a protein that binds cyclin G1 (CCNG1) and acts as a negative regulator of cell proliferation. It is regulated by TP53, CCNG1, and E2F1, and it interfaces with downstream effectors including CDK2, CCNE1, and CDK1 to control G1/S progression and DNA damage checkpoints. CCPG1 also interacts with MDM2 and 14-3-3 sigma, integrating signals from the p53 pathway. Loss of CCPG1 is expected to accelerate cell cycle entry and attenuate DNA damage responses, modeling oncogenic transformation processes.
In the HAP1 context, CCPG1 disruption yields a clear loss-of-function model, driving dysregulated proliferation and compromised checkpoint integrity. These phenotypes mirror CCPG1-associated cancers, including leukemias and solid tumors with altered CCPG1 expression. The near-haploid background ensures a direct link between genotype and phenotype, making this system ideal for studying CCPG1-dependent mechanisms and screening for genetic interactions or therapeutic vulnerabilities.
Typical applications include cell cycle profiling by flow cytometry, proliferation assays, and DNA damage response quantification through ??-H2AX foci imaging. Researchers can validate CCPG1-dependent signaling via Western blot and RT-qPCR, or investigate protein interactions by co-immunoprecipitation with CCNG1 or CDK2. The CCPG1 Knockout HAP1 Polyclonal Cells support functional genomics, drug target validation, and pathway dissection. For technical support or ordering, contact Ascent Research.
